OpenLB
Open Library of Bioscience
Advanced Search
Current medicinal chemistry
2025;32 (4): 729-752.

Statins, Allies against Antibiotic Resistance?

Mohammad Abavisani, Melika Hoseinzadeh, Reza Khayami, Mansoor Kodori, Saman Soleimanpour, Amirhossein Sahebkar
Author Information
  1. Mohammad Abavisani: Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
  2. Melika Hoseinzadeh: Dental Research Center, Mashhad Dental School, Mashhad University of Medical Sciences, Mashhad, Iran.
  3. Reza Khayami: Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  4. Mansoor Kodori: Non-communicable Diseases Research Center, Bam University of Medical Sciences, Bam, Iran.
  5. Saman Soleimanpour: Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  6. Amirhossein Sahebkar: Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
PMID: 37644745 DOI: 10.2174/0929867331666230829141301

Abstract

Due to the ever-increasing rate of antibacterial resistance, the search for effective antibacterial agents has become imperative. Researchers have investigated the potential antimicrobial properties of various classes of nonantibiotic drugs. Statins are a group of antihyperlipidemic drugs with several cholesterol-independent effects, including antiinflammatory, immune-modulating, antioxidant, and antibacterial effects. and studies have demonstrated the antibacterial properties of statins against various grampositive and gram-negative bacteria. Simvastatin and atorvastatin are the most potent members of the family. Their antibacterial effect can be attributed to several direct and indirect mechanisms. Bacterial invasion, growth, and virulence are affected by statins. However, since minimum inhibitory concentrations (MICs) are significantly higher than serum concentrations at the lipid-lowering dosage, indirect mechanisms have been suggested to explain the positive clinical results, including reducing inflammation and improving immune response capacity. Further, statins have shown promising results when combined with antibiotics and other antibacterial agents, such as triazenes and silver nanoparticles. Despite this, the controversial aspects of statins have cast doubt on their efficacy as a possible solution for antibacterial resistance, and further research is required. Consequently, this review will examine in detail the current clinical and findings and controversies regarding statins' antibacterial properties and their relevance to antibacterial resistance.

Keywords

Antibacterial resistance MICs antimicrobial atorvastatin simvastatin statins.

References

  1. Antimicrobial resistance: Global report on surveillance World Health Organization 2014
  2. Pulingam T.; Parumasivam T.; Gazzali A.M.; Sulaiman A.M.; Chee J.Y.; Lakshmanan M.; Chin C.F.; Sudesh K.; Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci 2022,170,106103 [DOI: 10.1016/j.ejps.2021.106103]
  3. Hansson K.; Brenthel A.; Imagining a post-antibiotic era: A cultural analysis of crisis and antibiotic resistance. Med Humanit 2022,48(3),381-388 [DOI: 10.1136/medhum-2022-012409]
  4. Abavisani M.; Goudarzi M.; Ghalavand Z.; Hajikhani B.; Rad Z.R.; Rad Z.R.; Hashemi A.; Evaluation of efflux pumps overexpression and β-lactamase genes among colistin resistant Pseudomonas aeruginosa. Gene Rep 2021,24,101301 [DOI: 10.1016/j.genrep.2021.101301]
  5. Abavisani M.; Khayami R.; Hoseinzadeh M.; Kodori M.; Kesharwani P.; Sahebkar A.; CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance. Drug Resist Updat 2023,68,100948 [DOI: 10.1016/j.drup.2023.100948]
  6. Larsson D.G.J.; Flach C.F.; Antibiotic resistance in the environment. Nat Rev Microbiol 2022,20(5),257-269 [DOI: 10.1038/s41579-021-00649-x]
  7. Andersson D.I.; Hughes D.; Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol 2014,12(7),465-478 [DOI: 10.1038/nrmicro3270]
  8. Abavisani M.; Bostanghadiri N.; Ghahramanpour H.; Kodori M.; Akrami F.; Fathizadeh H.; Hashemi A.; Rastegari-Pouyani M.; Colistin resistance mechanisms in Gram-negative bacteria: A focus on Escherichia coli. Lett Appl Microbiol 2023,76(2),ovad023 [DOI: 10.1093/lambio/ovad023]
  9. Andersson D.I.; Hughes D.; Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol Rev 2011,35(5),901-911 [DOI: 10.1111/j.1574-6976.2011.00289.x]
  10. Ashburn T.T.; Thor K.B.; Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004,3(8),673-683 [DOI: 10.1038/nrd1468]
  11. Blaha M.J.; Martin S.S.; How do statins work?: Changing paradigms with implications for statin allocation. J Am Coll Cardiol 2013,62(25),2392-2394 [DOI: 10.1016/j.jacc.2013.08.1626]
  12. Masadeh M.; Mhaidat N.; Alzoubi K.; Al-azzam S.; Alnasser Z.; Antibacterial activity of statins: A comparative study of Atorvastatin, Simvastatin, and Rosuvastatin. Ann Clin Microbiol Antimicrob 2012,11(1),13 [DOI: 10.1186/1476-0711-11-13]
  13. Bergman P.; Linde C.; Pütsep K.; Pohanka A.; Normark S.; Henriques-Normark B.; Andersson J.; Björkhem-Bergman L.; Studies on the antibacterial effects of statins-in vitro and in vivo. PLoS One 2011,6(8),e24394 [DOI: 10.1371/journal.pone.0024394]
  14. Qiao J.; Kontoyiannis D.P.; Wan Z.; Li R.; Liu W.; Antifungal activity of statins against Aspergillus species. Med Mycol 2007,45(7),589-593 [DOI: 10.1080/13693780701397673]
  15. Tavakkoli A.; Johnston T.P.; Sahebkar A.; Antifungal effects of statins. Pharmacol Ther 2020,208,107483 [DOI: 10.1016/j.pharmthera.2020.107483]
  16. Goldstein J.L.; Brown M.S.; Regulation of the mevalonate pathway. Nature 1990,343(6257),425-430 [DOI: 10.1038/343425a0]
  17. Kozarov E.; Padro T.; Badimon L.; View of statins as antimicrobials in cardiovascular risk modification. Cardiovasc Res 2014,102(3),362-374 [DOI: 10.1093/cvr/cvu058]
  18. Sahebkar A.; Kotani K.; Serban C.; Ursoniu S.; Mikhailidis D.P.; Jones S.R.; Ray K.K.; Blaha M.J.; Rysz J.; Toth P.P.; Muntner P.; Lip G.Y.; Banach M.; Lipid and blood pressure meta-analysis collaboration (LBPMC) group. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis 2015,241(2),433-442 [DOI: 10.1016/j.atherosclerosis.2015.05.022]
  19. Bland A.R.; Payne F.M.; Ashton J.C.; Jamialahmadi T.; Sahebkar A.; The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol Res 2022,175,105986 [DOI: 10.1016/j.phrs.2021.105986]
  20. Ferretti G.; Bacchetti T.; Sahebkar A.; Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 2015,60,50-73 [DOI: 10.1016/j.plipres.2015.08.003]
  21. Vahedian-Azimi A.; Mohammadi S.M.; Banach M.; Beni F.H.; Guest P.C.; Al-Rasadi K.; Jamialahmadi T.; Sahebkar, A. Improved COVID-19 outcomes following statin therapy: An updated systematic review and meta-analysis. BioMed Res Int 2021,1901772 [DOI: 10.1155/2021/1901772]
  22. Parizadeh S.M.R.; Azarpazhooh M.R.; Moohebati M.; Nematy M.; Ghayour-Mobarhan M.; Tavallaie S.; Rahsepar A.A.; Amini M.; Sahebkar A.; Mohammadi M.; Ferns G.A.A.; Simvastatin therapy reduces prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial. Lipids 2011,46(4),333-340 [DOI: 10.1007/s11745-010-3517-x]
  23. Sahebkar A.; Chew G.T.; Watts G.F.; Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 2014,56(1),47-66 [DOI: 10.1016/j.plipres.2014.07.002]
  24. Serban C.; Sahebkar A.; Ursoniu S.; Mikhailidis D.P.; Rizzo M.; Lip G.Y.; Kees Hovingh G.; Kastelein J.J.; Kalinowski L.; Rysz J.; Banach M.; A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Reports 2015,5,9902 [DOI: 10.1038/srep09902]
  25. Sohrevardi S.; Nasab F.; Mirjalili M.; Bagherniya M.; Tafti A.; Jarrahzadeh M.; Azarpazhooh M.; Saeidmanesh M.; Banach M.; Jamialahmadi T.; Sahebkar A.; Effect of atorvastatin on delirium status of patients in the intensive care unit: A randomized controlled trial. Arch Med Sci 2019,17(5),1423-1428 [DOI: 10.5114/aoms.2019.89330]
  26. Amin F.; Fathi F.; Reiner Ž.; Banach M.; Sahebkar A.; The role of statins in lung cancer. Arch Med Sci 2021,18(1),141-152 [DOI: 10.5114/aoms/123225]
  27. Hariyanto T.I.; Kurniawan A.; Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 2020,14(6),1613-1615 [DOI: 10.1016/j.dsx.2020.08.023]
  28. Shrivastava-Ranjan P.; Flint M.; Bergeron, É. McElroy, A.K.; Chatterjee, P.; Albariño, C.G.; Nichol, S.T.; Spiropoulou, C.F. Statins suppress Ebola virus infectivity by interfering with glycoprotein processing. MBio 2018,9(3),e00660-18 [DOI: 10.1128/mBio.00660-18]
  29. Rojo-Arreola L.; Long T.; Asarnow D.; Suzuki B.M.; Singh R.; Caffrey C.R.; Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS One 2014,9(1),e87594 [DOI: 10.1371/journal.pone.0087594]
  30. Parihar S.P.; Guler R.; Brombacher F.; Statins: A viable candidate for host-directed therapy against infectious diseases. Nat Rev Immunol 2019,19(2),104-117 [DOI: 10.1038/s41577-018-0094-3]
  31. Graziano T.S.; Cuzzullin M.C.; Franco G.C.; Schwartz-Filho H.O.; de Andrade E.D.; Groppo F.C.; Cogo-Müller K.; Statins and antimicrobial effects: Simvastatin as a potential drug against Staphylococcus aureus biofilm. PLoS One 2015,10(5),e0128098 [DOI: 10.1371/journal.pone.0128098]
  32. Cannon C.P.; Braunwald E.; McCabe C.H.; Rader D.J.; Rouleau J.L.; Belder R.; Joyal S.V.; Hill K.A.; Pfeffer M.A.; Skene A.M.; Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004,350(15),1495-1504 [DOI: 10.1056/NEJMoa040583]
  33. Jerwood S.; Cohen J.; Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2007,61(2),362-364 [DOI: 10.1093/jac/dkm496]
  34. Welsh A.M.; Kruger P.; Faoagali J.; Antimicrobial action of atorvastatin and rosuvastatin. Pathology 2009,41(7),689-691 [DOI: 10.3109/00313020903305860]
  35. Wang C.C.; Yang P.W.; Yang S.F.; Hsieh K.P.; Tseng S.P.; Lin Y.C.; Topical simvastatin promotes healing of Staphylococcus aureus -contaminated cutaneous wounds. Int Wound J 2016,13(6),1150-1157 [DOI: 10.1111/iwj.12431]
  36. Thangamani S.; Mohammad H.; Abushahba M.F.N.; Hamed M.I.; Sobreira T.J.P.; Hedrick V.E.; Paul L.N.; Seleem M.N.; Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci Rep 2015,5(1),16407 [DOI: 10.1038/srep16407]
  37. Whitaker E.; Alshammari A.; Bacteriostatic effect of simvastatin on selected oral Streptococci in vitro. Contemp Clin Dent 2017,8(1),59-63 [DOI: 10.4103/ccd.ccd_848_16]
  38. Emani S.; Gunjiganur G.; Mehta D.; Determination of the antibacterial activity of simvastatin against periodontal pathogens, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans: An in vitro study. Contemp Clin Dent 2014,5(3),377-382 [DOI: 10.4103/0976-237X.137959]
  39. Kamińska M.; Aliko A.; Hellvard A.; Bielecka E.; Binder V.; Marczyk A.; Potempa J.; Delaleu N.; Kantyka T.; Mydel P.; Effects of statins on multispecies oral biofilm identify simvastatin as a drug candidate targeting Porphyromonas gingivalis. J Periodontol 2019,90(6),637-646 [DOI: 10.1002/JPER.18-0179]
  40. Trombetta R.P.; Lowak K.; Albach A.; Lopez R.; Romano D.; Sanchez C.; The in vitro evaluation of statins as antimicrobials for trauma-related chronic infection. Research Square 2020 [DOI: 10.21203/rs.3.rs-15891/v1]
  41. Proctor R.; Respiration and small colony variants of Staphylococcus aureus. J Periodontol 2019,7(3) [DOI: 10.1128/microbiolspec.GPP3-0069-2019]
  42. Spoering A.L.; Lewis K.; Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 2001,183(23),6746-6751 [DOI: 10.1128/JB.183.23.6746-6751.2001]
  43. Mohammad S.; Nguyen H.; Nguyen M.; Abdel-Rasoul M.; Nguyen V.; Nguyen C.D.; Nguyen K.T.; Li L.; Kitzmiller J.P.; Pleiotropic effects of statins: Untapped potential for statin pharmacotherapy. Curr Vasc Pharmacol 2019,17(3),239-261 [DOI: 10.2174/1570161116666180723120608]
  44. Novack V.; Eisinger M.; Frenkel A.; Terblanche M.; Adhikari N.K.J.; Douvdevani A.; Amichay D.; Almog Y.; The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: A randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009,35(7),1255-1260 [DOI: 10.1007/s00134-009-1429-0]
  45. Fernandez R.; De Pedro V.J.; Artigas A.; Statin therapy prior to ICU admission: Protection against infection or a severity marker? Intensive Care Med 2006,32(1),160-164 [DOI: 10.1007/s00134-005-2743-9]
  46. Nagendran M.; McAuley D.F.; Kruger P.S.; Papazian L.; Truwit J.D.; Laffey J.G.; Thompson B.T.; Clarke M.; Gordon A.C.; Statin therapy for acute respiratory distress syndrome: An individual patient data meta-analysis of randomised clinical trials. Intensive Care Med 2017,43(5),663-671 [DOI: 10.1007/s00134-016-4649-0]
  47. Papazian L.; Roch A.; Charles P-E.; Penot-Ragon C.; Perrin G.; Roulier P.; Goutorbe P.; Lefrant J.Y.; Wiramus S.; Jung B.; Perbet S.; Hernu R.; Nau A.; Baldesi O.; Allardet-Servent J.; Baumstarck K.; Jouve E.; Moussa M.; Hraiech S.; Guervilly C.; Forel J.M.; Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: A randomized clinical trial. JAMA 2013,310(16),1692-1700 [DOI: 10.1001/jama.2013.280031]
  48. Ghayda R.A.; Han C.H.; Lee K.H.; Kim J.S.; Kim S.E.; Hong S.H.; Kim M.; Kronbichler A.; Tizaoui K.; Li H.; Koyanagi A.; Jacob L.; Kim M.S.; Yon D.K.; Lee S.W.; Kostev K.; Shin J.I.; Yang J.W.; Smith L.; The effect of statins on mortality among patients with infection: Umbrella review of meta-analyses. Eur Rev Med Pharmacol Sci 2021,25(6),2685-2695 [PMID: 33829455]
  49. Meregildo-Rodriguez E.D.; Chunga-Chévez E.V.; Gianmarco R.L.; Vásquez-Tirado G.A.; Further insights into to the role of statins against active tuberculosis: Systematic review and meta-analysis. Infez Med 2022,30(2),194-203 [PMID: 35693063]
  50. Lee C.C.; Lee M.G.; Hsu T.C.; Porta L.; Chang S.S.; Yo C.H.; Tsai K.C.; Lee M.; A population-based cohort study on the drug-specific effect of statins on sepsis outcome. Chest 2018,153(4),805-815 [DOI: 10.1016/j.chest.2017.09.024]
  51. Kruger P.; Bailey M.; Bellomo R.; Cooper D.J.; Harward M.; Higgins A.; Howe B.; Jones D.; Joyce C.; Kostner K.; McNeil J.; Nichol A.; Roberts M.S.; Syres G.; Venkatesh B.; A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013,187(7),743-750 [DOI: 10.1164/rccm.201209-1718OC]
  52. Yu Y.; Zhu C.; Liu C.; Gao Y.; Effect of prior atorvastatin treatment on the frequency of hospital acquired pneumonia and evolution of biomarkers in patients with acute ischemic stroke: A multicenter prospective study. Biomed Res Int 2017,2017,5642704 [DOI: 10.1155/2017/5642704]
  53. Jia M.; Huang W.; Li L.; Xu Z.; Wu L.; Statins reduce mortality after non-severe but not after severe pneumonia: A systematic review and meta-analysis. J Pharm Pharm Sci 2015,18(3),286-302 [DOI: 10.18433/J34307]
  54. Janda S.; Young A.; FitzGerald J.M.; Etminan M.; Swiston J.; The effect of statins on mortality from severe infections and sepsis: A systematic review and meta-analysis. J Crit Care 2010,25(4),656. e7-e22
  55. Ma Y.; Wen X.; Peng J.; Lu Y.; Guo Z.; Lu J.; Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality. PLoS One 2012,7(12),e51548 [DOI: 10.1371/journal.pone.0051548]
  56. Caffrey A.R.; Timbrook T.T.; Noh E.; Sakoulas G.; Opal S.M.; Nizet V.; LaPlante K.L.; Evidence to support continuation of statin therapy in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2017,61(3),e02228-e16 [DOI: 10.1128/AAC.02228-16]
  57. DeGorter M.K.; Tirona R.G.; Schwarz U.I.; Choi Y.H.; Dresser G.K.; Suskin N.; Myers K.; Zou G.; Iwuchukwu O.; Wei W.Q.; Wilke R.A.; Hegele R.A.; Kim R.B.; Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 2013,6(4),400-408 [DOI: 10.1161/CIRCGENETICS.113.000099]
  58. Link E.; Parish S.; Armitage J.; Bowman L.; Heath S.; Matsuda F.; Gut I.; Lathrop M.; Collins R.; SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008,359(8),789-799 [DOI: 10.1056/NEJMoa0801936]
  59. Hu S.Y.; Hsieh M.S.; Lin T.C.; Liao S.H.; Hsieh V.C.R.; Chiang J.H.; Chang Y.Z.; Statins improve the long-term prognosis in patients who have survived sepsis. Medicine (Baltimore) 2019,98(17),e15253 [DOI: 10.1097/MD.0000000000015253]
  60. Farghaly Aly U.; Aboutaleb H.A.; Abdellatif A.A.H.; Sameh Tolba N.; Formulation and evaluation of simvastatin polymeric nanoparticles loaded in hydrogel for optimum wound healing purpose. Drug Des Devel Ther 2019,13,1567-1580 [DOI: 10.2147/DDDT.S198413]
  61. Sameh N.F.; Aly U.; Abou Taleb H.A.; Abdellatif A.A.H.; Prospective role of simvastatin on wound healing: Review of the literature. J Bioequivalence Bioavailab 2018,10(2),36-42 [DOI: 10.4172/0975-0851.1000375]
  62. Liu C.; Zhu J.; Hai B.; Zhang W.; Wang H.; Leng H.; Xu Y.; Song C.; Single Intraosseous injection of simvastatin promotes endothelial progenitor cell mobilization, neovascularization, and wound healing in diabetic rats. Plast Reconstr Surg 2020,145(2),433-443 [DOI: 10.1097/PRS.0000000000006502]
  63. Spampinato S.F.; Caruso G.I.; De Pasquale R.; Sortino M.A.; Merlo S.; The treatment of impaired wound healing in diabetes: Looking among old drugs. Pharmaceuticals (Basel) 2020,13(4),60 [DOI: 10.3390/ph13040060]
  64. Salem H.F.; Nafady M.M.; Ewees M.G.E.L.D.; Hassan H.; Khallaf R.A.; Rosuvastatin calcium-based novel nanocubic vesicles capped with silver nanoparticles-loaded hydrogel for wound healing management: Optimization employing Box–Behnken design: In vitro and in vivo assessment. J Liposome Res 2022,32(1),45-61 [DOI: 10.1080/08982104.2020.1867166]
  65. Gupta M.; Kumar A.; Comparison of minimum inhibitory concentration (MIC) value of statin drugs: A systematic review. Antiinfect Agents 2018,17(1),4-19 [DOI: 10.2174/2211352516666180629124433]
  66. Willis J.A.; Cheburkanov V.; Chen S.; Soares J.M.; Kassab G.; Blanco K.C.; Bagnato V.S.; de Figueiredo P.; Yakovlev V.V.; Breaking down antibiotic resistance in methicillin-resistant Staphylococcus aureus: Combining antimicrobial photodynamic and antibiotic treatments. Proc Natl Acad Sci USA 2022,119(36),e2208378119 [DOI: 10.1073/pnas.2208378119]
  67. Al-Kuraishy H.M.; Al-Gareeb A.I.; Al-Buhadily A.K.; Rosuvastatin as forthcoming antibiotic or as adjuvant additive agent: In vitro novel antibacterial study. J Lab Physicians 2018,10(3),271-275 [DOI: 10.4103/JLP.JLP_170_17]
  68. Kornelsen V.; Unger M.; Kumar A.; Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030. Access Microbiol 2021,3(11),000288 [DOI: 10.1099/acmi.0.000288]
  69. Farmer A.R.; Murray C.K.; Mende K.; Akers K.S.; Zera W.C.; Beckius M.L.; Yun H.C.; Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for gram-negative rods. J Basic Microbiol 2013,53(4),336-339 [DOI: 10.1002/jobm.201100614]
  70. Manalo R.V.M.; Josol V.J.D.; Gloriani N.G.; The differential effects of atorvastatin co-administered with ampicillin on the bacterial growth and biofilm formation of Staphylococcus aureus. Curr Med Res Pract 2017,7(5),178-183 [DOI: 10.1016/j.cmrp.2017.08.002]
  71. Sankar S.; Thangamalai R.; Padmanaban S.; Kannan P.; Srinivasan M.; Arunaman C.; In-vitro synergistic antibacterial effect of atorvastatin and ampicillin against resistant Staphylococcus spp and E. coli isolated from bovine mastitis. bioRxiv 2019,695817
  72. García-Fernández E.; Koch G.; Wagner R.M.; Fekete A.; Stengel S.T.; Schneider J.; Membrane microdomain disassembly inhibits MRSA antibiotic resistance. Cell 2017,171(6),1354-1367 [DOI: 10.1016/j.cell.2017.10.012]
  73. Evans M.D.; Sammelson R.; McDowell S.; Differential effects of cotreatment of the antibiotic rifampin with host-directed therapeutics in reducing intracellular Staphylococcus aureus infection. PeerJ 2020,8,e10330 [DOI: 10.7717/peerj.10330]
  74. Lobato L.S.; Rosa P.S.; Ferreira J.S.; Neumann A.S.; da Silva M.G.; do Nascimento D.C.; Soares C.T.; Pedrini S.C.B.; Oliveira D.S.L.; Monteiro C.P.; Pereira G.M.B.; Ribeiro-Alves M.; Hacker M.A.; Moraes M.O.; Pessolani M.C.V.; Duarte R.S.; Lara F.A.; Statins increase rifampin mycobactericidal effect. Antimicrob Agents Chemother 2014,58(10),5766-5774 [DOI: 10.1128/AAC.01826-13]
  75. Skerry C.; Pinn M.L.; Bruiners N.; Pine R.; Gennaro M.L.; Karakousis P.C.; Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J Antimicrob Chemother 2014,69(9),2453-2457 [DOI: 10.1093/jac/dku166]
  76. Abdelaziz A.A.; El-Barrawy M.A.; El-Nagar R.A.M.; Potent synergistic combination of rosuvastatin and levofloxacin against Staphylococcus aureus: In vitro and in vivo study. J Appl Microbiol 2021,131(1),182-196 [DOI: 10.1111/jam.14968]
  77. Choudhury S.; Kannan K.; Pule Addison M.; Darzi S.A.; Singh V.; Singh T.U.; Thangamalai R.; Dash J.R.; Parida S.; Debroy B.; Paul A.; Mishra S.K.; Combined treatment with atorvastatin and imipenem improves survival and vascular functions in mouse model of sepsis. Vascul Pharmacol 2015,71,139-150 [DOI: 10.1016/j.vph.2015.03.012]
  78. Sarkeshikian S.S.; Ghadir M.R.; Alemi F.; Jalali S.M.; Hormati A.; Mohammadbeigi A.; Atorvastatin in combination with conventional antimicrobial treatment of Helicobacter pylori eradication: A randomized controlled clinical trial. J Gastroenterol Hepatol 2020,35(1),71-75 [DOI: 10.1111/jgh.14810]
  79. Rajabnia M.; Sadeghi A.; Abdi S.; Găman M-A.; Zali M.R.; Salehi N.; Effect of statins on Helicobacter pylori eradication rate: A systematic review and meta-analysis. GE Port J Gastroenterol 2022,29(5),322-330
  80. Figueiredo E.P.; Ribeiro J.M.; Nishio E.K.; Scandorieiro S.; Costa A.F.; Cardozo V.F.; de Oliveira A.G.; Durán, N.; Panagio, L.A.; Kobayashi, R.K.T.; Nakazato, G. New approach for simvastatin as an antibacterial: Synergistic effect with bio-synthesized silver nanoparticles against multidrug-resistant bacteria. Int J Nanomedicine 2019,14,7975-7985 [DOI: 10.2147/IJN.S211756]
  81. Rampelotto R.F.; Lorenzoni V.V.; Silva D.C.; Moraes G.A.; Serafin M.B.; Tizotti M.K.; Coelho S.; Zambiazi P.; Hörner M.; Hörner R.; Synergistic antibacterial effect of statins with the complex [1-(4-bromophenyl)-3-phenyltriazene N3-oxide-κ 2N1, O4](dimethylbenzylamine-κ2C1, N4)spalladium(II). Braz J Pharm Sci 2018,54(2),54 [DOI: 10.1590/s2175-97902018000217369]
  82. Domingues V.O.; Hörner R.; Reetz L.G.B.; Kuhn F.; Coser V.M.; Rodrigues J.N.; Bauchspiess R.; Pereira W.V.; Paraginski G.L.; Locatelli A.; Fank J.O.; Giglio V.F.; Hörner M.; In vitro evaluation of triazenes: DNA cleavage, antibacterial activity and cytotoxicity against acute myeloid leukemia cells. J Braz Chem Soc 2010,21(12),2226-2237 [DOI: 10.1590/S0103-50532010001200009]
  83. Mohammadi A.; Novel triazene dyes based on N-phenylpiperazine: Synthesis, anti-bacterial activity and solvatochromic properties. J Mol Liq 2014,193,69-73 [DOI: 10.1016/j.molliq.2013.12.024]
  84. Liu C.I.; Liu G.Y.; Song Y.; Yin F.; Hensler M.E.; Jeng W.Y.; Nizet V.; Wang A.H.J.; Oldfield E.; A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 2008,319(5868),1391-1394 [DOI: 10.1126/science.1153018]
  85. Clauditz A.; Resch A.; Wieland K.P.; Peschel A.; Götz F.; Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress. Infect Immun 2006,74(8),4950-4953 [DOI: 10.1128/IAI.00204-06]
  86. Friesen J.A.; Rodwell V.W.; The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol 2004,5(11),248 [DOI: 10.1186/gb-2004-5-11-248]
  87. Heuston S.; Begley M.; Gahan C.G.M.; Hill C.; Isoprenoid biosynthesis in bacterial pathogens. Microbiology (Reading) 2012,158(6),1389-1401 [DOI: 10.1099/mic.0.051599-0]
  88. Chow O.A.; von Köckritz-Blickwede M.; Bright A.T.; Hensler M.E.; Zinkernagel A.S.; Cogen A.L.; Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 2010,8(5),445-454 [DOI: 10.1016/j.chom.2010.10.005]
  89. Ko H.H.T.; Lareu R.R.; Dix B.R.; Hughes J.D.; In vitro antibacterial effects of statins against bacterial pathogens causing skin infections. Eur J Clin Microbiol Infect Dis 2018,37(6),1125-1135 [DOI: 10.1007/s10096-018-3227-5]
  90. de Jonge M.I.; Pehau-Arnaudet G.; Fretz M.M.; Romain F.; Bottai D.; Brodin P.; Honoré N.; Marchal G.; Jiskoot W.; England P.; Cole S.T.; Brosch R.; ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J Bacteriol 2007,189(16),6028-6034 [DOI: 10.1128/JB.00469-07]
  91. Parihar S.P.; Guler R.; Khutlang R.; Lang D.M.; Hurdayal R.; Mhlanga M.M.; Suzuki H.; Marais A.D.; Brombacher F.; Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 2014,209(5),754-763 [DOI: 10.1093/infdis/jit550]
  92. Haeri M.R.; White K.; Qharebeglou M.; Ansar M.M.; Cholesterol suppresses antimicrobial effect of statins. Iran J Basic Med Sci 2015,18(12),1253-1256 [PMID: 26877857]
  93. Li G.; Intestinal probiotics: Interactions with bile salts and reduction of cholesterol. Procedia Environ Sci 2012,12,1180-1186 [DOI: 10.1016/j.proenv.2012.01.405]
  94. Hildebrandt E.; McGee D.J.; Helicobacter pylori lipopolysaccharide modification, Lewis antigen expression, and gastric colonization are cholesterol-dependent. BMC Microbiol 2009,9(1),258 [DOI: 10.1186/1471-2180-9-258]
  95. McGee D.J.; George A.E.; Trainor E.A.; Horton K.E.; Hildebrandt E.; Testerman T.L.; Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37. Antimicrob Agents Chemother 2011,55(6),2897-2904 [DOI: 10.1128/AAC.00016-11]
  96. Salih F.A.; Inhibitory effect of Atorvastatin on the secretion of extracellular virulence products by Methicillin resistant Staphylococcus aureus. Zanco J Pure Appl Sci 2021,33(4),82-89
  97. López D.; Kolter R.; Functional microdomains in bacterial membranes. Genes Dev 2010,24(17),1893-1902 [DOI: 10.1101/gad.1945010]
  98. Foster T.J.; Can β-lactam antibiotics be resurrected to combat MRSA? Trends Microbiol 2019,27(1),26-38 [DOI: 10.1016/j.tim.2018.06.005]
  99. Horn M.P.; Knecht S.M.; Rushing F.L.; Birdsong J.; Siddall C.P.; Johnson C.M.; Abraham T.N.; Brown A.; Volk C.B.; Gammon K.; Bishop D.L.; McKillip J.L.; McDowell S.A.; Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J Pharmacol Exp Ther 2008,326(1),135-143 [DOI: 10.1124/jpet.108.137927]
  100. Pruefer D.; Makowski J.; Schnell M.; Buerke U.; Dahm M.; Oelert H.; Sibelius U.; Grandel U.; Grimminger F.; Seeger W.; Meyer J.; Darius H.; Buerke M.; Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 2002,106(16),2104-2110 [DOI: 10.1161/01.CIR.0000034048.38910.91]
  101. Hannachi N.; Fournier P.E.; Martel H.; Habib G.; Camoin-Jau L.; Statins potentiate the antibacterial effect of platelets on Staphylococcus aureus. Platelets 2021,32(5),671-676 [DOI: 10.1080/09537104.2020.1792434]
  102. Yamazaki H.; Suzuki M.; Aoki T.; Morikawa S.; Maejima T.; Sato F.; Sawanobori K.; Kitahara M.; Kodama T.; Saito Y.; Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: Relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells. J Atheroscler Thromb 2006,13(6),295-307 [DOI: 10.5551/jat.13.295]
  103. Mück A.O.; Seeger H.; Wallwiener D.; Class-specific pro-apoptotic effect of statins on human vascular endothelial cells. Z Kardiol 2004,93(5),398-402 [DOI: 10.1007/s00392-004-0081-5]
  104. Tapia-Pérez J.H.; Kirches E.; Mawrin C.; Firsching R.; Schneider T.; Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemother Pharmacol 2011,67(5),1193-1201 [DOI: 10.1007/s00280-010-1535-2]
  105. Björkhem-Bergman, L.; Lindh, J.D.; Bergman, P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol 2011,72(1),164-165 [DOI: 10.1111/j.1365-2125.2011.03907.x]
  106. Hennessy E.; Adams C.; Reen F.J.; O’Gara F.; Is there potential for repurposing statins as novel antimicrobials? Antimicrob Agents Chemother 2016,60(9),5111-5121 [DOI: 10.1128/AAC.00192-16]
  107. Bahrami A.; Parsamanesh N.; Atkin S.L.; Banach M.; Sahebkar A.; Effect of statins on toll-like receptors: A new insight to pleiotropic effects. Pharmacol Res 2018,135,230-238 [DOI: 10.1016/j.phrs.2018.08.014]
  108. Kandelouei T.; Abbasifard M.; Imani D.; Aslani S.; Razi B.; Fasihi M.; Shafiekhani S.; Mohammadi K.; Jamialahmadi T.; Reiner Ž.; Sahebkar A.; Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. Med Inflamm 2022,8732360 [DOI: 10.1155/2022/8732360]
  109. Koushki K.; Shahbaz S.K.; Mashayekhi K.; Sadeghi M.; Zayeri Z.D.; Taba M.Y.; Banach M.; Al-Rasadi K.; Johnston T.P.; Sahebkar A.; Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol 2021,60(2),175-199 [DOI: 10.1007/s12016-020-08791-9]
  110. Matsumoto M.; Einhaus D.; Gold E.S.; Aderem A.; Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J Immunol 2004,172(12),7377-7384 [DOI: 10.4049/jimmunol.172.12.7377]
  111. Zeiser R.; Immune modulatory effects of statins. Immunology 2018,154(1),69-75 [DOI: 10.1111/imm.12902]
  112. Gharehbeglou M.; Arjmand G.; Haeri M.R.; Khazeni M.; Nonselective mevalonate kinase inhibitor as a novel class of antibacterial agents. Cholesterol 2015,2015,147601 [DOI: 10.1155/2015/147601]
  113. Crusz S.M.; Balkwill F.R.; Inflammation and cancer: Advances and new agents. Nat Rev Clin Oncol 2015,12(10),584-596 [DOI: 10.1038/nrclinonc.2015.105]
  114. Weitz-Schmidt G.; Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002,23(10),482-487 [DOI: 10.1016/S0165-6147(02)02077-1]
  115. Nseir W.; Khateeb J.; Tatour I.; Haiek S.; Samara M.; Assy N.; Long-term statin therapy affects the severity of chronic gastritis. Helicobacter 2010,15(6),510-515 [DOI: 10.1111/j.1523-5378.2010.00803.x]
  116. Almog Y.; Statins, inflammation, and sepsis. Hypothesis Chest 2003,124(2),740-743 [DOI: 10.1378/chest.124.2.740]
  117. Arnaud C.; Mach F.; Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum 2006,54(2),390-392 [DOI: 10.1002/art.21757]
  118. Braga Filho J.A.F.; Abreu A.G.; Rios C.E.P.; Trovão, L.O.; Silva, D.L.F.; Cysne, D.N.; Nascimento, J.R.; Fortes, T.S.; Silva, L.A.; Guerra, R.N.M.; Maciel, M.C.G.; Serezani, C.H.; Nascimento, F.R.F. Prophylactic treatment with simvastatin modulates the immune response and increases animal survival following lethal sepsis infection. Front Immunol 2018,9,2137 [DOI: 10.3389/fimmu.2018.02137]
  119. McDowell S.A.; Ma Y.; Kusano R.; Akinbi H.T.; Simvastatin is protective during Staphylococcus aureus pneumonia. Curr Pharm Biotechnol 2011,12(9),1455-1462 [DOI: 10.2174/138920111798281027]
  120. Deepe G.S.; Buesing W.R.; Deciphering the pathways of death of Histoplasma capsulatum-infected macrophages: Implications for the immunopathogenesis of early infection. J Immunol 2012,188(1),334-344 [DOI: 10.4049/jimmunol.1102175]
  121. Gyetvai A.; Emri T.; Takács K.; Dergez T.; Fekete A.; Pesti M.; Pócsi I.; Lenkey B.; Lovastatin possesses a fungistatic effect against Candida albicans, but does not trigger apoptosis in this opportunistic human pathogen. FEMS Yeast Res 2006,6(8),1140-1148 [DOI: 10.1111/j.1567-1364.2006.00097.x]
  122. del Real G.; Jiménez-Baranda S.; Mira E.; Lacalle R.A.; Lucas P.; Gómez-Moutón C.; Alegret M.; Peña J.M.; Rodríguez-Zapata M.; Alvarez-Mon M.; Martínez-A C.; Mañes S.; Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004,200(4),541-547 [DOI: 10.1084/jem.20040061]
  123. Cines D.B.; Pollak E.S.; Buck C.A.; Loscalzo J.; Zimmerman G.A.; McEver R.P.; Pober J.S.; Wick T.M.; Konkle B.A.; Schwartz B.S.; Barnathan E.S.; McCrae K.R.; Hug B.A.; Schmidt A.M.; Stern D.M.; Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998,91(10),3527-3561 [PMID: 9572988]
  124. Jain M.K.; Ridker P.M.; Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005,4(12),977-987 [DOI: 10.1038/nrd1901]
  125. Laws M.; Shaaban A.; Rahman K.M.; Antibiotic resistance breakers: Current approaches and future directions. FEMS Microbiol Rev 2019,43(5),490-516 [DOI: 10.1093/femsre/fuz014]
  126. Andersson D.I.; Balaban N.Q.; Baquero F.; Courvalin P.; Glaser P.; Gophna U.; Kishony R.; Molin S.; Tønjum T.; Antibiotic resistance: Turning evolutionary principles into clinical reality. FEMS Microbiol Rev 2020,44(2),171-188 [DOI: 10.1093/femsre/fuaa001]
  127. Rolain J.M.; Food and human gut as reservoirs of transferable antibiotic resistance encoding genes. Front Microbiol 2013,4,173 [DOI: 10.3389/fmicb.2013.00173]
  128. Sommer M.O.A.; Dantas G.; Church G.M.; Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 2009,325(5944),1128-1131 [DOI: 10.1126/science.1176950]
  129. Le Bastard Q.; Al-Ghalith G.A.; Grégoire M.; Chapelet G.; Javaudin F.; Dailly E.; Batard E.; Knights D.; Montassier E.; Systematic review: Human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther 2018,47(3),332-345 [DOI: 10.1111/apt.14451]
  130. Zhao C.; Hu Y.; Chen H.; Li B.; Cao L.; Xia J.; Yin Y.; An in vitro evaluation of the effects of different statins on the structure and function of human gut bacterial community. PLoS One 2020,15(3),e0230200 [DOI: 10.1371/journal.pone.0230200]
  131. Le Roy C.; Bowyer R.; Carr V.; Costeira R.; Castillo-Fernandez J.; Martin T.; Host genetic and environmental factors shape the human gut resistome. BioRxiv 2020 [DOI: 10.1101/2020.05.18.092973]
  132. Mahboobi S.K.; Shohat E.Z.; Jellinek S.P.; Rose M.; Systemic infections can decrease the threshold of statin-induced muscle injury. South Med J 2006,99(4),403-404 [DOI: 10.1097/01.smj.0000209273.52754.86]
  133. Vincent A.; Miller J.A.L.; Statins for sepsis: A cautionary note. Intensive Care Med 2006,32(5),795 [DOI: 10.1007/s00134-006-0143-4]
  134. Golomb B.A.; Evans M.A.; Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008,8(6),373-418 [DOI: 10.2165/0129784-200808060-00004]
  135. Brealey D.A.; Singer M.; Terblanche M.; Potential metabolic consequences of statins in sepsis. Crit Care Med 2011,39(6),1514-1520 [DOI: 10.1097/CCM.0b013e31820eb74f]
  136. Kellick K.A.; Bottorff M.; Toth P.P.; A clinician’s guide to statin drug-drug interactions. J Clin Lipid 2014,8(3),S30-S46
  137. Lee A.J.; Maddix D.S.; Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001,35(1),26-31 [DOI: 10.1345/aph.10177]
  138. Patel A.M.; Shariff S.; Bailey D.G.; Juurlink D.N.; Gandhi S.; Mamdani M.; Gomes T.; Fleet J.; Hwang Y.J.; Garg A.X.; Statin toxicity from macrolide antibiotic coprescription: A population-based cohort study. Ann Intern Med 2013,158(12),869-876 [DOI: 10.7326/0003-4819-158-12-201306180-00004]
  139. Alzahrani T.; Liappis A.P.; Baddour L.M.; Karasik P.E.; Statin use and the risk of cardiovascular implantable electronic device infection: A cohort study in a veteran population. Pacing Clin Electrophysiol 2018,41(3),284-289 [DOI: 10.1111/pace.13285]
  140. Coban A.Y.; Tekeli H.O.; Güney A.K.; Durupinar B.; Investigation of the in vitro antibacterial effects of statins. Mikrobiyol Bul 2010,44(1),161-163 [PMID: 20455414]
  141. Matzneller P.; Manafi M.; Zeitlinger M.; Antimicrobial effect of statins: Organic solvents might falsify microbiological testing results. Int J Clin Pharmacol Ther 2011,49(11),666-671 [DOI: 10.5414/CP201581]
  142. Ting M.; Whitaker E.J.; Albandar J.M.; Systematic review of the in vitro effects of statins on oral and perioral microorganisms. Eur J Oral Sci 2016,124(1),4-10 [DOI: 10.1111/eos.12239]
  143. Quivey R.; Reducing dental caries. 2012
  144. Radwan S.; Ezzat O.; Antimicrobial effect and immunomodulation of atorvastatin. J Am Sci 2012,8(9),1012-1016
  145. Alshammari A.; In vitro effect of statins on Streptococcus mutans, Streptococcus sanguis, and Streptococcus salvarius 2016
  146. Sarabhai S.; Dhaliwal L.K.; Capalash N.; Sharma P.; Effect of atorvastatin and rosuvastatin on quorum sensing, biofilm formation and bacterial motilities of Pseudomonas aeruginosa. Int J Pharma Bio Sci 2015,6(1),1-8

MeSH Term

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anti-Bacterial Agents
Microbial Sensitivity Tests
Drug Resistance, Bacterial
Animals
Gram-Negative Bacteria
Gram-Positive Bacteria

Chemicals

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anti-Bacterial Agents
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0antibacterialstatinsresistancepropertiesagentsantimicrobialvariousdrugsStatinsseveraleffectsincludingatorvastatinindirectmechanismsconcentrationsMICsclinicalresultsDueever-increasingratesearcheffectivebecomeimperativeResearchersinvestigatedpotentialclassesnonantibioticgroupantihyperlipidemiccholesterol-independentantiinflammatoryimmune-modulatingantioxidantstudiesdemonstratedgrampositivegram-negativebacteriaSimvastatinpotentmembersfamilyeffectcanattributeddirectBacterialinvasiongrowthvirulenceaffectedHoweversinceminimuminhibitorysignificantlyhigherserumlipid-loweringdosagesuggestedexplainpositivereducinginflammationimprovingimmuneresponsecapacityshownpromisingcombinedantibioticstriazenessilvernanoparticlesDespitecontroversialaspectscastdoubtefficacypossiblesolutionresearchrequiredConsequentlyreviewwillexaminedetailcurrentfindingscontroversiesregardingstatins'relevanceAlliesAntibioticResistance?Antibacterialsimvastatin

Similar Articles

Cited By